BEDFORD, Mass., March 25, 2013 /PRNewswire/ -- Instrumentation Laboratory (IL), a company of the Werfen Group, today announced total worldwide sales in 2012 of €476.4M (612.3M USD). In its two major business segments, Hemostasis and Critical Care Diagnostics, IL achieved significant revenue growth of 12.4% and 10.1%, respectively. Additionally, based on data from company estimates and third party research, IL confirmed their global market leadership position in Hemostasis diagnostics. In the Critical Care diagnostics market, IL was the fastest growing manufacturer of benchtop systems worldwide.
In 2012, IL placed a record number of both Hemostasis and Critical Care systems worldwide. Of particular note, IL successfully transitioned to a direct business model in the United States, Canada, China and Australia for their Hemostasis product line. With North America representing the largest Hemostasis market in the world, and China, the fastest growing market in the world, this move unlocks tremendous growth potential for IL. The company estimates that, excluding the impact of the transition to a direct business model, its Hemostasis end-user sales worldwide grew by 8%.
"2012 was a year of very significant, positive change for IL. Notably, our shift to a direct business model in several key markets enables us to be closer to our customers, react immediately to their needs and share our expertise with them," said Ramon Benet, Chief Executive Officer at IL. "The outstanding customer feedback we have received speaks to the quality of our employees, the new infrastructure we developed, and our entire product line. While we are already the global leader in Hemostasis testing, we look forward to continued strong growth in 2013 and beyond."
In North America, where sales, service and support employees have worked directly with Critical Care customers for decades, more than 200 new Hemostasis employees were hired. At IL's headquarters, a Hemostasis Customer Training Center was built, along with an Innovation Center where customers can meet directly with R&D scientists and engineers to help shape and enhance products in development. Concurrently, in mainland China, including Hong Kong and Macao, direct distribution channels for IL Hemostasis products were established with dedicated sales, service and support teams and a Technical Service Call Center. Additionally, in Australia, Werfen Group established a new headquarters to provide direct sales, service and support for IL's Hemostasis product line.
IL now provides direct support to more than 13,000 Hemostasis laboratories around the world, solidifying their position as a leader and innovator in Hemostasis testing solutions. Worldwide sales of the ACL TOP® Family of Testing Systems, IL's flagship Hemostasis product offering, grew significantly throughout the world. A new member, the ACL TOP 300 CTS, was introduced in 2012, leveraging the Family's standardized platform and allowing additional flexibility in Hemostasis testing. The product is quickly penetrating the global Hemostasis market as a stand-alone system and as companion to the other members of the ACL TOP Family: the ACL TOP 500 CTS and ACL TOP 700 CTS/LAS.
IL has consistently led innovation in the Hemostasis reagent market with their HemosIL®, the most sophisticated automated assays for the diagnosis and management of coagulopathies, and in 2012, IL continued this trend. Several highly anticipated new assays to complement the ACL TOP system, including a dRVVT test for Lupus Anticoagulants and a Protein S Activity assay with enhanced stability, were successfully introduced. New assays for IL's ACL AcuStar® chemiluminescent system, included the HemosIL AcuStar HIT assay panel, comprised of HemosIL AcuStar HIT-IgG and HemosIL AcuStar HIT-Ab assays, and the HemosIL AcuStar VWF assay panel, with VWF: Ag and VWF:RCo, all based on chemiluminescent technology for high sensitivity and precision.
On the Critical Care diagnostics side, sales of IL's flagship GEM Premier 4000 analyzer with Intelligent Quality Management (iQM®) grew considerably throughout the world spurred by the introduction of PLUS technology featuring faster touchscreen responsiveness and integrated wireless features. In addition, IL completed worldwide commercialization of GEMweb® Plus 200 Custom Connectivity offering operator certification and advanced regulatory management.
HemosIL AcuStar VWF and HemosIL AcuStar HIT assays are not currently 510(k) cleared.
Instrumentation Laboratory ( www.ilus.com ), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include Critical Care systems, Hemostasis systems and Information Management systems. IL's GEM® product offerings, part of the Critical Care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM®), GEM Premier 3500, GEMweb® Plus Custom Connectivity, and complementary products GEM PCL Plus, a portable coagulation analyzer, GEM OPL CO-Oximeter, and GEMdraw arterial blood samplers. IL's Hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP 700, ACL TOP 700 LAS, ACL TOP 700 CTS, ACL TOP 500 CTS and ACL TOP 300 CTS. IL also offers the ACL AcuStar®, ACL ELITE®, other Hemostasis analyzers and the HemosIL® line of reagents. IL is based in Bedford, Massachusetts.
The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.
SOURCE Instrumentation Laboratory